Isis Gains Patents For Novel Antisense Chemistry
Isis Pharmaceuticals, based in California, USA, has received notices of allowance for four US patents, two of which cover novel purine modifications that are used in the company's antisense oligonucleotide drugs. A third notice of allowance covers two chiral forms of the ISIS 2105 compound which will be useful in enhancing the drug properties of future generations of antisense compounds.
In addition to the composition of matter notice Isis received in April on ISIS 2105, as well as the one on ISIS 2922, this notice further solidifies Isis' ownership of ISIS 2105, one of the company's leading antisense drug opportunities, it says.
The fourth notice covers a novel method for large-scale production of an important manufacturing intermediate used in antisense oligonucleotide chemical synthesis. Isis is currently manufacturing all of its own compounds for both research and clinical development. The company is developing a significant proprietary position and expertise in large-scale synthesis, analysis and purification of antisense oligonucleotides, it claims.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze